Association between proton pump inhibitors and rhabdomyolysis risk: a post-marketing surveillance using FDA adverse event reporting system (FAERS) database

por Altebainawi, Ali F., Alfaraj, Lulwa A., Alharbi, Amjad A., Alkhuraisi, Fadwa F., Alshammari, Thamir M.
Publicado 2023

Efficacy and Safety of Luspatercept in the Treatment of β-Thalassemia: A Systematic Review

por Dighriri, Ibrahim M, Alrabghi, Khawlah K, Sulaiman, Dilveen M, Alruwaili, Abdulrahman M, Alanazi, Nader S, Al-Sadiq, Al-maha A, Hadadi, ‌‏Amal M, Sahli, Bushra Y, Qasem, Basil A, Alotaibi, Manal T, Asiri, Taif T, Majrashi, Salman M, Alotibia, Noura T, Alhamyani, Afnan T, Alharbi, Amjad A
Publicado 2022